Top Markets
#1 Zora Zora +31.06%
#2 Tutorial Tutorial +29.43%
#3 Wrapped STX (Velar) Wrapped STX (Velar) +25.39%
#4 GALA GALA +25.12%
#5 Fabric Protocol Fabric Protocol +24.31%
#6 Pieverse Pieverse +23.14%
#7 HashKey Platform Token HashKey Platform Token +22.61%
#8 Arowana Arowana +22.11%
#9 EXOD EXOD +22.08%
#10 Derive Derive +21.73%
Coin of the day
Zora Zora
Settings
Language
ENGLISH
Currency
USD
Theme
Orexo AB Orexo AB

Orexo AB

ORX
Rank in Stocks #24896
Orexo AB (publ), a specialty pharmaceutical company, develops and... Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
Share Price
$1.58
Market Cap
$55.40M
Change (1 day)
0.71%
Change (1 year)
-28.43%
Country
SE
Trade Orexo AB (ORX)

Category

Healthcare
Revenue for Orexo AB (ORX)
Revenue in Aug 2026 TTM: 0
According to Orexo AB latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Orexo AB from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $2.54B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 $830.81M -
US
Sino Biopharmaceutical Limited Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited
1177.HK
 $4.55B -
HK